A Phase 4 interventional study of HYQVIA and KIOVIG in Primary Immunodeficiency Diseases (PID), sponsored by Baxalta now part of Shire. Completed at 20 sites in 8 countries. Open to participants aged 2 Years to 17 Years. Per ClinicalTrials.gov, last updated 2023-01-11.
Sponsored by Baxalta now part of Shire (part of Takeda) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 29 studies testing Immunoglobulin G in Primary Immunodeficiency Diseases — 2 open to participants now, 4 under way, 4 of them phase 3. Immunoglobulin G · Primary Immunodeficiency Diseases.
Among the 29 studies testing Immunoglobulin G in Primary Immunodeficiency Diseases, this one is the 16th largest by enrollment of the 28 interventional ones that give a count, is one of 3 that started in 2017, is one of 3 in phase 4, and was the 21st registered.
211 studies on the registry are indexed under Primary Immunodeficiency Diseases; 51 are open to participants now.
Browse Primary Immunodeficiency Diseases studies →2 of the 29 studies testing Immunoglobulin G in Primary Immunodeficiency Diseases are open now. Recruiting first, the newest first:
Azidus Brasil
Ages 2–60
Azidus Brasil
Ages 6–60
Immunoglobulin G: first FDA approval 1944 (Baygam, Gamastan S/D), first EMA approval 2006. What it is approved for, and how studies give it, is on its page →
Of the 35 Primary Immunodeficiency Diseases studies recruiting now, 12 (34%) set no upper age limit and 10 (29%) stop at 75 or younger; 28 take children under 18; 11 take healthy volunteers.
This study: 2 Years to 17 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
29 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 6 · Phase 3 23 · Phase 4 3
First in 2000; this study’s year is marked. 3 started in 2017.
This study's enrollment of 42 is above the median of 36 across 125 interventional studies indexed under Primary Immunodeficiency Diseases.
Median enrollment 45 across the 28 interventional studies. Of the 25 that completed or were terminated, 15 (60%) have results posted.
This tab as a report to print or save as PDF → With an account.
26 of 29 have an industry lead sponsor. The 10 most frequent:
This study is registered under Baxalta now part of Shire, one of the names counted as Takeda. Under that name alone:
Baxalta now part of Shire is the lead sponsor of 111 studies on the registry; none are open to participants now.
Of its 18 completed or terminated interventional studies of FDA-regulated products, 16 (89%) have results posted.
23 studies in Primary Immunodeficiency Diseases by Takeda: 2 open now, 3 under way, 1 of them phase 3. Of 19 finished, 12 (63%) have results posted.
Among the 23 studies in Primary Immunodeficiency Diseases by Takeda, this one is the 11th largest by enrollment of the 18 interventional ones that give a count, is one of 2 that started in 2017, is one of 2 in phase 4, and was the 11th registered.
Takeda’s Primary Immunodeficiency Diseases studies by the year they started, since 2002.
2 of the studies testing Immunoglobulin G in Primary Immunodeficiency Diseases that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04640142Phase 3OctapharmaStudy to Evaluate the Pharmacokinetics, Efficacy, Tolerability, and Safety of Subcutaneous Human Immunoglobulin (Newnorm) in Patients With Primary Immunodeficiency Diseases | 2026-11 |
| NCT04944979Phase 3Kedrion S.p.A.Clinical Assessment of Pharmacokinetics, Efficacy, and Safety of 10% IVIg in Pediatric PID Patients (KIDCARES10) | 2026-12 |
Add all 2 to your calendar (.ics) → With an account.
Among the 29 studies testing Immunoglobulin G in Primary Immunodeficiency Diseases, from their registry updates:
Among Takeda’s 23 in Primary Immunodeficiency Diseases:
This tab as a report to print or save as PDF → With an account.
The purpose of the study is to acquire additional data on safety, tolerability and immunogenicity of HyQvia in pediatric (age two to \<18 years) patients with Primary Immunodeficiency Diseases (PIDD)
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Abnormal laboratory values at screening meeting any one of the following criteria (abnormal tests may be repeated once to determine if they are persistent):
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ramp up period for participants who were not treated with HyQvia prior to this study
Biological: HYQVIA
Participants who were treated with HyQvia prior to this study, and those who completed the ramp up period (Epoch 1). After one year in Epoch 2, participants with anti-rHuPH20 antibody titer \<160 at all time-points during the study will complete the study termination/completion visit at the next possible occasion. Participants with anti-rHuPH20 antibody titer \>=160 during the study and/or at the last measurement will continue for an additional two years of HyQvia treatment and observation.
Biological: HYQVIA
Safety follow-up for participants whose anti-rHuPH20 antibody titer was \>= 160 during Epoch 1 or Epoch 2 and who experience either a related serious adverse event (SAE) or a related severe adverse event (AE)
Biological: KIOVIG · Biological: Cuvitru
Drug pages: Immunoglobulin G · Hyaluronoglucosaminidase
Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase (IGI, 10% with rHuPH20)
Also known as: IGI 10% with rHuPH20
100 mg/ml solution for Immune Globulin Intravenous Infusion
Also known as: IGIV 10%, IGI 10%
200 mg/ml solution for Immune Globulin Subcutaneous Injection
Also known as: IGSC 20%, IGI 20%
Safety: Number of Participants With Any Severe Related Treatment-emergent Adverse Events (TEAEs) Per Infusion (Excluding Infections)
An Adverse Event (AE) was defined as any untoward medical occurrence in a participant administered an investigational product (IP) that does not necessarily have a causal relationship with the treatment. TEAEs were the AEs with onset after date-time of first dose of IP, or any medical condition present prior to the start of IP but increased in severity or relationship after date-time of first dose of IP. TEAEs that were recorded as "possibly related" or "probably related" to HYQVIA were considered HYQVIA-related adverse events. Number of participants with any severe related TEAEs (excluding infections) was reported.
Time frame: From start of study drug administration up to 20 months
Safety: Rate of Any Severe Related TEAEs Per Infusion (Excluding Infections)
An AE was defined as any untoward medical occurrence in a participant administered an IP that does not necessarily have a causal relationship with the treatment. TEAEs were the AEs with onset after date-time of first dose of IP, or any medical condition present prior to the start of IP but increased in severity or relationship after date-time of first dose of IP. TEAEs that were recorded as "possibly related" or "probably related" to HYQVIA were considered HYQVIA-related adverse events. Severe related TEAEs rate per infusion was calculated as number of severe related TEAEs/total number of infusions administered to participants in the analysis set. Rate of any severe related TEAEs per infusion (excluding infections) was reported.
Time frame: From start of study drug administration up to 20 months
Safety: Number of Participants With Any Related Serious TEAEs Per Infusion (Excluding Infections)
TEAEs were the AEs with onset after date-time of first dose of IP, or any medical condition present prior to the start of IP but increased in severity or relationship after date-time of first dose of IP. A serious TEAE was an AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect or was otherwise considered medically important. TEAEs that were recorded as "possibly related" or "probably related" to HYQVIA were considered HYQVIA-related adverse events. Number of participants with any related serious TEAEs per infusion (excluding infections) was reported.
Time frame: From start of study drug administration up to 20 months
Safety: Rate of Any Related Serious TEAEs Per Infusion (Excluding Infections)
TEAEs were the AEs with onset after date-time of first dose of IP, or any medical condition present prior to the start of IP but increased in severity or relationship after date-time of first dose of IP. A serious TEAE was an AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged in-patient hospitalization; congenital anomaly/birth defect or was otherwise considered medically important. TEAEs that were recorded as "possibly related" or "probably related" to HYQVIA were considered HYQVIA-related adverse events. Rate of related serious TEAEs per infusion was calculated as number of related serious TEAEs/total number of infusions administered to participants in the analysis set. Rate of any related serious TEAEs per Infusion (excluding infections) was reported.
Time frame: From start of study drug administration up to 20 months
Efficacy: Change From Baseline in Total Serum Trough Levels of Immunoglobulin G (IgG) at Month 12
Change from baseline in total serum trough levels of IgG in Epoch 1 and 2 was reported. Baseline was defined as the last non-missing value before the initial dose of HYQVIA.
Time frame: Baseline, Month 12
Efficacy: Change From Baseline in Serum Trough Levels of IgG Subclasses at Month 12
Change from baseline in Serum trough levels of IgG subclasses 1, 2, 3, and 4 in Epoch 1 and 2 was reported. Baseline was defined as the last non-missing value before the initial dose of HYQVIA.
Time frame: Baseline, Month 12
Efficacy: Change From Baseline in Trough Levels of Specific Antibodies to Clostridium Tetani Toxoid IgG at Month 12
Change from baseline in trough levels of specific antibodies in clostridium tetani toxoid IgG at Month 12 was reported. Baseline was defined as the last non-missing value before the initial dose of HYQVIA. Here, IU/ml was defined as "International units per milliliter".
Time frame: Baseline, Month 12
Efficacy: Change From Baseline in Trough Levels of Specific Antibodies to Hepatitis B Virus (HBV) at Month 12
Change from baseline in trough levels of specific antibodies in HBV at Month 12 was reported. Baseline was defined as the last non-missing value before the initial dose of HYQVIA.
Time frame: Baseline, Month 12
Efficacy: Change From Baseline in Trough Levels of Specific Antibodies to Haemophilus Influenzae B IgG at Month 12
Change from baseline in trough levels of specific antibodies in Haemophilus influenzae B IgG at Month 12 was reported. Baseline was defined as the last non-missing value before the initial dose of HYQVIA.
Time frame: Baseline, Month 12
Safety: Percentage of Participants Who Achieved a Treatment Interval of Three or Four Weeks in Epoch 2
Percentage of participants who achieved a treatment interval of three or four weeks in Epoch 2 was reported.
Time frame: Up to 20 months
Safety: Percentage of Participants Who Maintained a Treatment Interval of Three or Four Weeks in Epoch 2 up to 12 Months
Percentage of participants who maintained a treatment interval of three or four weeks in Epoch 2 up to 12 months was reported.
Time frame: Up to 12 months
Safety: Number of Participants With Local TEAEs (Excluding Infections)
TEAEs were the AEs with onset after date-time of first dose of IP, or any medical condition present prior to the start of IP but increased in severity or relationship after date-time of first dose of IP. Number of Participants with local TEAEs (excluding infections) was reported.
Time frame: From start of study drug administration up to 20 months
Safety: Rate of Local TEAEs Per Infusion (Excluding Infections)
Rate of local TEAEs per infusion was calculated as number of local adverse events/total number of infusions administered to participants in the analysis set. Only events are included which start prior to participants start date of non-response. Rate of local TEAEs per infusion (excluding infections) was reported.
Time frame: From start of study drug administration up to 20 months
Safety: Number of Participants With Local Adverse Reaction (Excluding Infections)
Adverse reaction was defined as any TEAE that meets any of the following criteria: 1) A TEAE considered by either the investigator and/or the sponsor to be possibly or probably related to IP administration, or; 2) A TEAE that begins during infusion of IP or within 72 hours following the end of IP infusion, or; 3) A TEAE for which causality assessment is missing or indeterminate. Number of participants with local adverse reactions (excluding infections) was reported.
Time frame: From start of study drug administration up to 20 months
Safety: Rate of Local Adverse Reaction Per Infusion (Excluding Infections)
Rate of local adverse reaction per infusion was calculated as number of local adverse reaction events/total number of infusions administered to participants in the analysis set. Rate of local adverse reactions per infusion (excluding infections) was reported.
Time frame: From start of study drug administration up to 20 months
Safety: Number of Participants With Systemic TEAEs (Excluding Infections)
TEAEs were the AEs with onset after date-time of first dose of IP, or any medical condition present prior to the start of IP but increased in severity or relationship after date-time of first dose of IP. Number of participants with systemic TEAEs (excluding infections) was reported..
Time frame: From start of study drug administration up to 20 months
Safety: Rate of Systemic TEAEs Per Infusion (Excluding Infections)
Rate of systemic TEAEs per infusion was calculated as number of systemic adverse events/total number of infusions administered to participants in the analysis set. Rate of systemic TEAEs per infusion was assessed based on events per infusion.
Time frame: From start of study drug administration up to 20 months
Safety: Number of Participants With Systemic Adverse Reaction (Excluding Infections)
Adverse reaction was defined as any TEAE that meets any of the following criteria: 1) A TEAE considered by either the investigator and/or the sponsor to be possibly or probably related to IP administration, or; 2) A TEAE that begins during infusion of IP or within 72 hours following the end of IP infusion, or; 3) A TEAE for which causality assessment is missing or indeterminate. Number of participants with systemic adverse reaction (excluding infections) was reported.
Time frame: From start of study drug administration up to 20 months
Safety: Rate of Systemic Adverse Reaction Per Infusion (Excluding Infections)
Rate of Systemic adverse reactions per infusion was calculated as number of systemic adverse reaction events/total number of infusions administered to participants in the analysis set. Rate of systemic adverse reactions per infusion (excluding infections) was reported.
Time frame: From start of study drug administration up to 20 months
Safety: Number of Participants With Any TEAEs (Excluding Infections)
TEAEs were the AEs with onset after date-time of first dose of IP, or any medical condition present prior to the start of IP but increased in severity or relationship after date-time of first dose of IP. Number of participants with any TEAEs (excluding infections) was reported.
Time frame: From start of study drug administration up to 20 months
Safety: Rate of TEAEs Per Infusion (Excluding Infections)
Rate of TEAEs per infusion was calculated as number of adverse events/total number of infusions administered to participants in the analysis set. Rate of TEAEs per infusion (excluding infections) was reported.
Time frame: From start of study drug administration up to 20 months
Safety: Number of Participants With Any Adverse Reactions (Excluding Infections)
Adverse reaction was defined as any TEAE that meets any of the following criteria: 1) A TEAE considered by either the investigator and/or the sponsor to be possibly or probably related to IP administration, or; 2) A TEAE that begins during infusion of IP or within 72 hours following the end of IP infusion, or; 3) A TEAE for which causality assessment is missing or indeterminate. Number of participants with any adverse reactions (excluding infections) was reported.
Time frame: From start of study drug administration up to 20 months
Safety: Rate of Any Adverse Reaction Per Infusion (Excluding Infections)
Rate of all adverse reactions per infusion was calculated as number of adverse reaction events/total number of infusions administered to participants in the analysis set. Rate of any adverse reactions per infusion (excluding infections) was reported.
Time frame: From start of study drug administration up to 20 months
Safety: Number of Participants With Any Temporally Associated TEAEs (Excluding Infections)
Temporally-associated TEAEs were defined as TEAEs which begin during infusion of IP or within 72 hours following the end of IP infusion. Number of participants with any temporally associated TEAEs (excluding infections) was reported.
Time frame: From start of study drug administration up to 20 months
Safety: Rate of Any Temporally Associated TEAEs Per Infusion (Excluding Infections)
Rate of any temporally associated TEAEs per infusion was calculated as number of temporally associated adverse events/total number of infusions administered to participants in the analysis set. Temporally-associated TEAEs were defined as TEAEs which begin during infusion of IP or within 72 hours following the end of IP infusion. Rate of any temporally associated TEAEs per infusion (excluding infections) was reported.
Time frame: From start of study drug administration up to 20 months
Safety: Number of Participants With Any Related (Causally) and/or Temporally Associated TEAEs (Excluding Infections)
Number of participants with any related (causally) and/or temporally associated TEAEs (excluding infections) was reported. Temporally-associated TEAEs were defined as TEAEs which begin during infusion of IP or within 72 hours following the end of IP infusion.
Time frame: From start of study drug administration up to 20 months
Safety: Rate of Any Related (Causally) and/or Temporally Associated TEAEs Per Infusion (Excluding Infections)
Rate of any related (causally) and/or temporally associated TEAEs per infusion was calculated as number of related and/or temporally associated adverse events/ total number of infusions administered to participants in the analysis set. TEAEs recorded in the study database as "possibly related" or "probably related" to HYQVIA are considered HYQVIA-related adverse events. Temporally-associated TEAEs were defined as TEAEs which begin during infusion of IP or within 72 hours following the end of IP infusion. Rate of any related (causally) and/or temporally associated TEAEs per infusion (excluding infections) was reported.
Time frame: From start of study drug administration up to 20 months
Safety: Number of Participants With Any Serious TEAEs (Excluding Infections)
Serious TEAE were the AEs that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged in-patient hospitalization; congenital anomaly/birth defect or was otherwise considered medically important. Number of participants with any serious TEAEs (excluding infections) was reported.
Time frame: From start of study drug administration up to 20 months
Safety: Rate of Serious TEAEs Per Infusion (Excluding Infections)
Rate of serious TEAEs per infusion was calculated as number of serious adverse events/total number of infusions administered to participants in the analysis set. Rate of serious TEAEs per infusion (excluding infections) was reported.
Time frame: From start of study drug administration up to 20 months
Safety: Number of Participants Who Developed Positive Titer (>=160) of Binding or Neutralizing Antibodies to rHuPH20
Number of participants who developed positive titer (\>=160) of binding or neutralizing antibodies to rHuPH20 was reported.
Time frame: From start of study drug administration up to 20 months
Other Analysis: Number of Infusions Per Month
Number of infusions per month was calculated as total number of infusions per duration of treatment (days) \* 30.4 days per month.
Time frame: Up to 20 months
Other Analysis: Number of Infusion Sites (Needle-Sticks) Per Infusion
Number of infusion sites (needle-sticks) per infusion was calculated as total number of infusion sites / total number of infusions. Only infusions with complete data available were included.
Time frame: Up to 20 months
Other Analysis: Number of Infusion Sites (Needle-Sticks) Per Month
Number of infusion sites per month was calculated as total number of infusion sites / duration of treatment (days) \* 30.4 days. Only infusions with complete data available were included.
Time frame: Up to 20 months
Other Analysis: Duration of Infusion
The duration of infusion was defined as the difference between the end time and the start time of the HyQvia infusion.
Time frame: From start of study drug administration up to 20 months.
Other Analysis: Maximum Infusion Rate Per Site
Maximum infusion rate per site was reported.
Time frame: Up to 20 months
Other Analysis: Infusion Volume Per Site
Infusion volume per site was calculated as actual IgG volume (milliliter \[mL\]) / total number of infusion sites (hour) used.
Time frame: Up to 20 months
Other Analysis: Number of Infusions That Were Interrupted or Stopped Due to an AE
Number of infusions that were interrupted or Stopped due to an AE was reported.
Time frame: Up to 20 months
Other Analysis: Number of Weeks to Reach Final 3 or 4-week Dose Interval in Epoch 1
Final dose interval, defined as three or four weeks infusion interval in Epoch 1 of treatment period, was reported.
Time frame: Up to 20 months
Health Related Quality of Life (HR QoL): Change From Baseline in Pediatric Quality of Life Questionnaire (PedsQL)
PedsQL Generic Core Scale (GCS) was used for QOL assessment. It encompasses 4 dimensions (physical functioning \[PF\], emotional functioning \[EF\], social functioning \[SF\], school functioning \[ScF\]). Age groups are: Toddler (2-4 years), Young child (5-7 years), Child (8-12 years), and Teens (13-\<18 years). Depending on the participants age, the questionnaire may be completed by either the participant or the parent/caregiver as appropriate. For the Toddler group, the PedsQL GCS consisted of 21 items, using a 5-point Likert scale (0 to 4); for all other groups, the PedsQL consisted of 23 items, with a 3-point Likert scale (0, 2, 4) for the young child, and a 5-point Likert scale for the child and teens groups. All Scores were transformed on a scale from 0 to 100 where 0=100, 1=75, 2=50, 3=25, and 4=0. Higher scores indicate better quality of life. A negative change from baseline indicates worse quality of life. Baseline: last non-missing value before the initial dose of HYQVIA.
Time frame: Baseline up to 20 months
HRQoL: Change From Baseline in EuroQoL (Quality of Life)-5 Dimensions (EQ-5D)
EQ-5D considered five attributes of quality of life evaluation, that is, mobility, self-care, usual activity, pain/discomfort, and anxiety/depression. Each dimension had five possible levels: 1 (no problems); 2 (slight problems); 3 (moderate problems); 4 (severe problems), and; 5 (extreme problems). The participants rating of their current HRQoL state was recorded using a standard vertical 20-cm visual analog scale (EQ-VAS), which ranged from 0 to 100, where 0 indicated worst imaginable health state and 100 was best imaginable health state. Baseline was defined as the last non-missing value before the initial dose of HYQVIA. A negative change from baseline indicates worse health state.
Time frame: Baseline up to 20 months
HR QoL: Change From Baseline in Treatment Satisfaction Questionnaire for Medication-9 (TSQM-9)
TSQM-9 is a 9-item, validated, self-administered instrument to assess participants satisfaction with medication. It consists of 3 subscales: effectiveness, convenience and global satisfaction. The scores were computed by adding items for each domain, i.e. 1 to 3 for effectiveness, 4 - 6 for convenience and 7 to 9 for global satisfaction. The lowest possible score (1 for each item and 3 for all 3 subscales) was subtracted from the composite score and divided by the greatest possible score range. The greatest range was (7-1)\*3 items = 18 for the effectiveness and convenience, and (5-1)\*3 items = 12 for global satisfaction . The item scores of each of the 3 domains are summed and transformed to create a score of 0 (extremely dissatisfied) to 100 (extremely satisfied). Higher score indicated greater satisfaction in that domain. A negative change from baseline indicates less satisfaction in that domain. Baseline was defined as the last non-missing value before the initial dose of HYQVIA.
Time frame: Baseline up to 20 months
The study was conducted at 16 sites from 30 May 2017 to 15 January 2021. A total of 42 participants were enrolled and treated in this study. This study consisted of 3 treatment periods: Epoch 1, Epoch 2 and Epoch 3. Participant with anti-rHuPH20 antibody titer greater than or equal to (\>=) 160 during Epoch 1 or Epoch 2 and who experienced either a related serious adverse event or related severe adverse event were followed to Epoch 3.
| Milestone | HyQvia New Starters | HyQvia Pre-treated |
|---|---|---|
| Started | 23 | 19 |
| Started epoch 1 | 23 | 0 |
| Completed epoch 1 | 22 | 0 |
| Started epoch 2 | 22 | 19 |
| Completed epoch 2 | 22 | 17 |
| Moved from epoch 2 to epoch 3 | 1 | 0 |
| Completed epoch 3 | 1 | 0 |
| Completed | 22 | 17 |
| Not completed | 1 | 2 |
| Withdrew: Withdrawal by subject | 1 | 2 |
An Adverse Event (AE) was defined as any untoward medical occurrence in a participant administered an investigational product (IP) that does not necessarily have a causal relationship with the treatment. TEAEs were the AEs with onset after date-time of first dose of IP, or any medical condition present prior to the start of IP but increased in severity or relationship after date-time of first dose of IP. TEAEs that were recorded as "possibly related" or "probably related" to HYQVIA were considered HYQVIA-related adverse events. Number of participants with any severe related TEAEs (excluding infections) was reported.
| Participants | HyQvia New Starters | HyQvia Pre-treated |
|---|---|---|
| Safety: Number of Participants With Any Severe Related Treatment-emergent Adverse Events (TEAEs) Per Infusion (Excluding Infections) | 1 | 0 |
An AE was defined as any untoward medical occurrence in a participant administered an IP that does not necessarily have a causal relationship with the treatment. TEAEs were the AEs with onset after date-time of first dose of IP, or any medical condition present prior to the start of IP but increased in severity or relationship after date-time of first dose of IP. TEAEs that were recorded as "possibly related" or "probably related" to HYQVIA were considered HYQVIA-related adverse events. Severe related TEAEs rate per infusion was calculated as number of severe related TEAEs/total number of infusions administered to participants in the analysis set. Rate of any severe related TEAEs per infusion (excluding infections) was reported.
| Number of Severe Related TEAEs/Infusion | HyQvia New Starters | HyQvia Pre-treated |
|---|---|---|
| Safety: Rate of Any Severe Related TEAEs Per Infusion (Excluding Infections) | 0.004 | 0 |
TEAEs were the AEs with onset after date-time of first dose of IP, or any medical condition present prior to the start of IP but increased in severity or relationship after date-time of first dose of IP. A serious TEAE was an AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect or was otherwise considered medically important. TEAEs that were recorded as "possibly related" or "probably related" to HYQVIA were considered HYQVIA-related adverse events. Number of participants with any related serious TEAEs per infusion (excluding infections) was reported.
| Participants | HyQvia New Starters | HyQvia Pre-treated |
|---|---|---|
| Safety: Number of Participants With Any Related Serious TEAEs Per Infusion (Excluding Infections) | 0 | 0 |
TEAEs were the AEs with onset after date-time of first dose of IP, or any medical condition present prior to the start of IP but increased in severity or relationship after date-time of first dose of IP. A serious TEAE was an AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged in-patient hospitalization; congenital anomaly/birth defect or was otherwise considered medically important. TEAEs that were recorded as "possibly related" or "probably related" to HYQVIA were considered HYQVIA-related adverse events. Rate of related serious TEAEs per infusion was calculated as number of related serious TEAEs/total number of infusions administered to participants in the analysis set. Rate of any related serious TEAEs per Infusion (excluding infections) was reported.
| Number of Related Serious TEAEs/Infusion | HyQvia New Starters | HyQvia Pre-treated |
|---|---|---|
| Safety: Rate of Any Related Serious TEAEs Per Infusion (Excluding Infections) | 0 | 0 |
Change from baseline in total serum trough levels of IgG in Epoch 1 and 2 was reported. Baseline was defined as the last non-missing value before the initial dose of HYQVIA.
| Gram per liter (g/L) | HyQvia New Starters | HyQvia Pre-treated |
|---|---|---|
| Efficacy: Change From Baseline in Total Serum Trough Levels of Immunoglobulin G (IgG) at Month 12 | 0.035 ± 1.6983 | -0.709 ± 2.6576 |
Change from baseline in Serum trough levels of IgG subclasses 1, 2, 3, and 4 in Epoch 1 and 2 was reported. Baseline was defined as the last non-missing value before the initial dose of HYQVIA.
| g/L | HyQvia New Starters | HyQvia Pre-treated |
|---|---|---|
| IgG Subclass 1 : Changed at Month 12 | -0.813 ± 1.1087 | -0.467 ± 1.5976 |
| IgG Subclass 2 : Changed at Month 12 | 0.000 ± 0.8944 | -0.667 ± 1.3452 |
| IgG Subclass 3 : Changed at Month 12 | 0.000 ± 0.3651 | 0.133 ± 0.3519 |
| IgG Subclass 4 : Changed at Month 12 | 0.094 ± 0.0854 | -0.027 ± 0.0799 |
Change from baseline in trough levels of specific antibodies in clostridium tetani toxoid IgG at Month 12 was reported. Baseline was defined as the last non-missing value before the initial dose of HYQVIA. Here, IU/ml was defined as "International units per milliliter".
| IU/ml | HyQvia New Starters | HyQvia Pre-treated |
|---|---|---|
| Efficacy: Change From Baseline in Trough Levels of Specific Antibodies to Clostridium Tetani Toxoid IgG at Month 12 | -0.218 ± 0.9345 | — |
Change from baseline in trough levels of specific antibodies in HBV at Month 12 was reported. Baseline was defined as the last non-missing value before the initial dose of HYQVIA.
| International units per liter (IU/L) | HyQvia New Starters | HyQvia Pre-treated |
|---|---|---|
| Efficacy: Change From Baseline in Trough Levels of Specific Antibodies to Hepatitis B Virus (HBV) at Month 12 | 167.875 ± 147.4887 | — |
Change from baseline in trough levels of specific antibodies in Haemophilus influenzae B IgG at Month 12 was reported. Baseline was defined as the last non-missing value before the initial dose of HYQVIA.
| Milligram per liter (mg/L) | HyQvia New Starters | HyQvia Pre-treated |
|---|---|---|
| Efficacy: Change From Baseline in Trough Levels of Specific Antibodies to Haemophilus Influenzae B IgG at Month 12 | -0.017 ± 0.9503 | — |
Percentage of participants who achieved a treatment interval of three or four weeks in Epoch 2 was reported.
| Percentage of participants | HyQvia New Starters | HyQvia Pre-treated |
|---|---|---|
| Every 3 weeks treatment interval | 39.1 | 15.8 |
| Every 4 weeks treatment interval | 60.9 | 84.2 |
Percentage of participants who maintained a treatment interval of three or four weeks in Epoch 2 up to 12 months was reported.
| Percentage of participants | HyQvia New Starters | HyQvia Pre-treated |
|---|---|---|
| Safety: Percentage of Participants Who Maintained a Treatment Interval of Three or Four Weeks in Epoch 2 up to 12 Months | 87.0 | 78.9 |
TEAEs were the AEs with onset after date-time of first dose of IP, or any medical condition present prior to the start of IP but increased in severity or relationship after date-time of first dose of IP. Number of Participants with local TEAEs (excluding infections) was reported.
| Participants | HyQvia New Starters | HyQvia Pre-treated |
|---|---|---|
| Safety: Number of Participants With Local TEAEs (Excluding Infections) | 11 | 3 |
Rate of local TEAEs per infusion was calculated as number of local adverse events/total number of infusions administered to participants in the analysis set. Only events are included which start prior to participants start date of non-response. Rate of local TEAEs per infusion (excluding infections) was reported.
| Number of local TEAEs/Infusion | HyQvia New Starters | HyQvia Pre-treated |
|---|---|---|
| Safety: Rate of Local TEAEs Per Infusion (Excluding Infections) | 0.082 | 0.009 |
Adverse reaction was defined as any TEAE that meets any of the following criteria: 1) A TEAE considered by either the investigator and/or the sponsor to be possibly or probably related to IP administration, or; 2) A TEAE that begins during infusion of IP or within 72 hours following the end of IP infusion, or; 3) A TEAE for which causality assessment is missing or indeterminate. Number of participants with local adverse reactions (excluding infections) was reported.
| Participants | HyQvia New Starters | HyQvia Pre-treated |
|---|---|---|
| Safety: Number of Participants With Local Adverse Reaction (Excluding Infections) | 11 | 3 |
Rate of local adverse reaction per infusion was calculated as number of local adverse reaction events/total number of infusions administered to participants in the analysis set. Rate of local adverse reactions per infusion (excluding infections) was reported.
| Number of Local AR events/Infusion | HyQvia New Starters | HyQvia Pre-treated |
|---|---|---|
| Safety: Rate of Local Adverse Reaction Per Infusion (Excluding Infections) | 0.080 | 0.009 |
TEAEs were the AEs with onset after date-time of first dose of IP, or any medical condition present prior to the start of IP but increased in severity or relationship after date-time of first dose of IP. Number of participants with systemic TEAEs (excluding infections) was reported..
| Participants | HyQvia New Starters | HyQvia Pre-treated |
|---|---|---|
| Safety: Number of Participants With Systemic TEAEs (Excluding Infections) | 15 | 10 |
Rate of systemic TEAEs per infusion was calculated as number of systemic adverse events/total number of infusions administered to participants in the analysis set. Rate of systemic TEAEs per infusion was assessed based on events per infusion.
| Number of systemic TEAEs/Infusion | HyQvia New Starters | HyQvia Pre-treated |
|---|---|---|
| Safety: Rate of Systemic TEAEs Per Infusion (Excluding Infections) | 0.138 | 0.142 |
Adverse reaction was defined as any TEAE that meets any of the following criteria: 1) A TEAE considered by either the investigator and/or the sponsor to be possibly or probably related to IP administration, or; 2) A TEAE that begins during infusion of IP or within 72 hours following the end of IP infusion, or; 3) A TEAE for which causality assessment is missing or indeterminate. Number of participants with systemic adverse reaction (excluding infections) was reported.
| Participants | HyQvia New Starters | HyQvia Pre-treated |
|---|---|---|
| Safety: Number of Participants With Systemic Adverse Reaction (Excluding Infections) | 3 | 1 |
Rate of Systemic adverse reactions per infusion was calculated as number of systemic adverse reaction events/total number of infusions administered to participants in the analysis set. Rate of systemic adverse reactions per infusion (excluding infections) was reported.
| Number of systemic AR events/Infusion | HyQvia New Starters | HyQvia Pre-treated |
|---|---|---|
| Safety: Rate of Systemic Adverse Reaction Per Infusion (Excluding Infections) | 0.011 | 0.012 |
TEAEs were the AEs with onset after date-time of first dose of IP, or any medical condition present prior to the start of IP but increased in severity or relationship after date-time of first dose of IP. Number of participants with any TEAEs (excluding infections) was reported.
| Participants | HyQvia New Starters | HyQvia Pre-treated |
|---|---|---|
| Safety: Number of Participants With Any TEAEs (Excluding Infections) | 18 | 11 |
Rate of TEAEs per infusion was calculated as number of adverse events/total number of infusions administered to participants in the analysis set. Rate of TEAEs per infusion (excluding infections) was reported.
| Number of TEAEs/Infusion | HyQvia New Starters | HyQvia Pre-treated |
|---|---|---|
| Safety: Rate of TEAEs Per Infusion (Excluding Infections) | 0.220 | 0.151 |
Adverse reaction was defined as any TEAE that meets any of the following criteria: 1) A TEAE considered by either the investigator and/or the sponsor to be possibly or probably related to IP administration, or; 2) A TEAE that begins during infusion of IP or within 72 hours following the end of IP infusion, or; 3) A TEAE for which causality assessment is missing or indeterminate. Number of participants with any adverse reactions (excluding infections) was reported.
| Participants | HyQvia New Starters | HyQvia Pre-treated |
|---|---|---|
| Safety: Number of Participants With Any Adverse Reactions (Excluding Infections) | 12 | 3 |
Rate of all adverse reactions per infusion was calculated as number of adverse reaction events/total number of infusions administered to participants in the analysis set. Rate of any adverse reactions per infusion (excluding infections) was reported.
| Adverse reaction event/Infusion | HyQvia New Starters | HyQvia Pre-treated |
|---|---|---|
| Safety: Rate of Any Adverse Reaction Per Infusion (Excluding Infections) | 0.091 | 0.021 |
Temporally-associated TEAEs were defined as TEAEs which begin during infusion of IP or within 72 hours following the end of IP infusion. Number of participants with any temporally associated TEAEs (excluding infections) was reported.
| Participants | HyQvia New Starters | HyQvia Pre-treated |
|---|---|---|
| Safety: Number of Participants With Any Temporally Associated TEAEs (Excluding Infections) | 13 | 6 |
Rate of any temporally associated TEAEs per infusion was calculated as number of temporally associated adverse events/total number of infusions administered to participants in the analysis set. Temporally-associated TEAEs were defined as TEAEs which begin during infusion of IP or within 72 hours following the end of IP infusion. Rate of any temporally associated TEAEs per infusion (excluding infections) was reported.
| Temporally associated TEAEs/Infusion | HyQvia New Starters | HyQvia Pre-treated |
|---|---|---|
| Safety: Rate of Any Temporally Associated TEAEs Per Infusion (Excluding Infections) | 0.106 | 0.027 |
Number of participants with any related (causally) and/or temporally associated TEAEs (excluding infections) was reported. Temporally-associated TEAEs were defined as TEAEs which begin during infusion of IP or within 72 hours following the end of IP infusion.
| Participants | HyQvia New Starters | HyQvia Pre-treated |
|---|---|---|
| Safety: Number of Participants With Any Related (Causally) and/or Temporally Associated TEAEs (Excluding Infections) | 13 | 6 |
Rate of any related (causally) and/or temporally associated TEAEs per infusion was calculated as number of related and/or temporally associated adverse events/ total number of infusions administered to participants in the analysis set. TEAEs recorded in the study database as "possibly related" or "probably related" to HYQVIA are considered HYQVIA-related adverse events. Temporally-associated TEAEs were defined as TEAEs which begin during infusion of IP or within 72 hours following the end of IP infusion. Rate of any related (causally) and/or temporally associated TEAEs per infusion (excluding infections) was reported.
| Related Temporally TEAEs/Infusion | HyQvia New Starters | HyQvia Pre-treated |
|---|---|---|
| Safety: Rate of Any Related (Causally) and/or Temporally Associated TEAEs Per Infusion (Excluding Infections) | 0.112 | 0.033 |
Serious TEAE were the AEs that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged in-patient hospitalization; congenital anomaly/birth defect or was otherwise considered medically important. Number of participants with any serious TEAEs (excluding infections) was reported.
| Participants | HyQvia New Starters | HyQvia Pre-treated |
|---|---|---|
| Safety: Number of Participants With Any Serious TEAEs (Excluding Infections) | 0 | 3 |
Rate of serious TEAEs per infusion was calculated as number of serious adverse events/total number of infusions administered to participants in the analysis set. Rate of serious TEAEs per infusion (excluding infections) was reported.
| Number of serious TEAEs/Infusion | HyQvia New Starters | HyQvia Pre-treated |
|---|---|---|
| Safety: Rate of Serious TEAEs Per Infusion (Excluding Infections) | 0 | 0.012 |
Number of participants who developed positive titer (\>=160) of binding or neutralizing antibodies to rHuPH20 was reported.
| Participants | HyQvia New Starters | HyQvia Pre-treated |
|---|---|---|
| Participants with positive titer (>=160) of binding antibodies | 0 | 0 |
| Participants with neutralizing antibodies | 0 | 0 |
Number of infusions per month was calculated as total number of infusions per duration of treatment (days) \* 30.4 days per month.
| Infusion/Month | HyQvia New Starters | HyQvia Pre-treated |
|---|---|---|
| Other Analysis: Number of Infusions Per Month | 1.30 (1.1 to 1.7) | 1.20 (1.0 to 1.6) |
Number of infusion sites (needle-sticks) per infusion was calculated as total number of infusion sites / total number of infusions. Only infusions with complete data available were included.
| Infusion sites (needle sticks)/Infusion | HyQvia New Starters | HyQvia Pre-treated |
|---|---|---|
| Other Analysis: Number of Infusion Sites (Needle-Sticks) Per Infusion | 1.65 ± 0.442 | 1.25 ± 0.403 |
Number of infusion sites per month was calculated as total number of infusion sites / duration of treatment (days) \* 30.4 days. Only infusions with complete data available were included.
| Infusion sites (needle sticks)/Month | HyQvia New Starters | HyQvia Pre-treated |
|---|---|---|
| Other Analysis: Number of Infusion Sites (Needle-Sticks) Per Month | 1.96 ± 0.780 | 1.33 ± 0.634 |
The duration of infusion was defined as the difference between the end time and the start time of the HyQvia infusion.
| Minutes | HyQvia New Starters | HyQvia Pre-treated |
|---|---|---|
| Other Analysis: Duration of Infusion | 75.0 (10 to 215) | 101.0 (15 to 257) |
Maximum infusion rate per site was reported.
| Milliliter per hour per site (mL/h/site) | HyQvia New Starters | HyQvia Pre-treated |
|---|---|---|
| Other Analysis: Maximum Infusion Rate Per Site | 181.54 ± 77.772 | 171.73 ± 90.203 |
Infusion volume per site was calculated as actual IgG volume (milliliter \[mL\]) / total number of infusion sites (hour) used.
| Milliliter per hour | HyQvia New Starters | HyQvia Pre-treated |
|---|---|---|
| Other Analysis: Infusion Volume Per Site | 112.39 ± 71.427 | 178.23 ± 98.523 |
Number of infusions that were interrupted or Stopped due to an AE was reported.
| Infusions | HyQvia New Starters | HyQvia Pre-treated |
|---|---|---|
| Number of infusions interrupted | 4 | 0 |
| Number of infusions Stopped | 1 | 0 |
Final dose interval, defined as three or four weeks infusion interval in Epoch 1 of treatment period, was reported.
| Weeks | HyQvia New Starters | HyQvia Pre-treated |
|---|---|---|
| Other Analysis: Number of Weeks to Reach Final 3 or 4-week Dose Interval in Epoch 1 | 6.10 (3.0 to 7.0) | — |
PedsQL Generic Core Scale (GCS) was used for QOL assessment. It encompasses 4 dimensions (physical functioning \[PF\], emotional functioning \[EF\], social functioning \[SF\], school functioning \[ScF\]). Age groups are: Toddler (2-4 years), Young child (5-7 years), Child (8-12 years), and Teens (13-\<18 years). Depending on the participants age, the questionnaire may be completed by either the participant or the parent/caregiver as appropriate. For the Toddler group, the PedsQL GCS consisted of 21 items, using a 5-point Likert scale (0 to 4); for all other groups, the PedsQL consisted of 23 items, with a 3-point Likert scale (0, 2, 4) for the young child, and a 5-point Likert scale for the child and teens groups. All Scores were transformed on a scale from 0 to 100 where 0=100, 1=75, 2=50, 3=25, and 4=0. Higher scores indicate better quality of life. A negative change from baseline indicates worse quality of life. Baseline: last non-missing value before the initial dose of HYQVIA.
| Score on a scale | HyQvia New Starters | HyQvia Pre-treated |
|---|---|---|
| PF in Toddler: Change up to 20 months | — | -3.12 ± NA |
| PF in Young child: Change up to 20 months | — | -31.25 ± NA |
| PF in Child: Change up to 20 months | 7.81 ± 6.626 | -71.88 ± NA |
| PF in Teens: Change up to 20 months | -12.65 ± 12.726 | 13.75 ± 24.664 |
| EF in Toddler: Change up to 20 months | — | 0.00 ± NA |
| EF in Young child: Change up to 20 months | — | -25.00 ± NA |
| EF in Child: Change up to 20 months | 5.00 ± 14.142 | -20.00 ± NA |
| EF in Teens: Change up to 20 months | -13.33 ± 7.638 | 1.25 ± 14.307 |
| SF in Toddler: Change up to 20 months | — | 0.00 ± NA |
| SF in Young child: Change up to 20 months | — | -35.00 ± NA |
| SF in Child: Change up to 20 months | -20.00 ± 0.000 | -40.00 ± NA |
| SF in Teens: Change up to 20 months | 1.67 ± 7.638 | 8.00 ± 11.511 |
| ScF in Toddler: Change up to 20 months | — | 25.00 ± NA |
| ScF in Young child: Change up to 20 months | — | -45.00 ± NA |
| ScF in Child: Change up to 20 months | -12.50 ± 10.607 | -65.00 ± NA |
| ScF in Teens: Change up to 20 months | 1.67 ± 7.638 | -17.00 ± 24.135 |
EQ-5D considered five attributes of quality of life evaluation, that is, mobility, self-care, usual activity, pain/discomfort, and anxiety/depression. Each dimension had five possible levels: 1 (no problems); 2 (slight problems); 3 (moderate problems); 4 (severe problems), and; 5 (extreme problems). The participants rating of their current HRQoL state was recorded using a standard vertical 20-cm visual analog scale (EQ-VAS), which ranged from 0 to 100, where 0 indicated worst imaginable health state and 100 was best imaginable health state. Baseline was defined as the last non-missing value before the initial dose of HYQVIA. A negative change from baseline indicates worse health state.
| Score on a scale | HyQvia New Starters | HyQvia Pre-treated |
|---|---|---|
| HRQoL: Change From Baseline in EuroQoL (Quality of Life)-5 Dimensions (EQ-5D) | -8.60 ± 11.149 | -4.43 ± 15.447 |
TSQM-9 is a 9-item, validated, self-administered instrument to assess participants satisfaction with medication. It consists of 3 subscales: effectiveness, convenience and global satisfaction. The scores were computed by adding items for each domain, i.e. 1 to 3 for effectiveness, 4 - 6 for convenience and 7 to 9 for global satisfaction. The lowest possible score (1 for each item and 3 for all 3 subscales) was subtracted from the composite score and divided by the greatest possible score range. The greatest range was (7-1)\*3 items = 18 for the effectiveness and convenience, and (5-1)\*3 items = 12 for global satisfaction . The item scores of each of the 3 domains are summed and transformed to create a score of 0 (extremely dissatisfied) to 100 (extremely satisfied). Higher score indicated greater satisfaction in that domain. A negative change from baseline indicates less satisfaction in that domain. Baseline was defined as the last non-missing value before the initial dose of HYQVIA.
| Score on a scale | HyQvia New Starters | HyQvia Pre-treated |
|---|---|---|
| Effectiveness: Change at 20 months | 12.96 ± 32.552 | -0.92 ± 10.783 |
| Convenience: Change at 20 months | 14.81 ± 27.398 | 4.63 ± 15.873 |
| Global satisfaction: Change 20 months | 11.90 ± 10.911 | -2.38 ± 19.518 |
Collected over From start of study drug administration up to end of the study (up to 43 months). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| HyQvia New Starters | 0/23 (0%) | 2/23 (8.7%) | 22/23 (95.7%) |
| HyQvia Pre-treated | 0/19 (0%) | 5/19 (26.3%) | 14/19 (73.7%) |
| Event | HyQvia New Starters | HyQvia Pre-treated |
|---|---|---|
| Idiopathic orbital inflammationEye disorders | 0/23 | 1/19 |
| Dental cariesGastrointestinal disorders | 0/23 | 1/19 |
| Inflammatory bowel diseaseGastrointestinal disorders | 0/23 | 1/19 |
| PyrexiaGeneral disorders | 0/23 | 1/19 |
| Pilonidal cystInfections and infestations | 0/23 | 1/19 |
| Acute sinusitisInfections and infestations | 0/23 | 1/19 |
| PharyngitisInfections and infestations | 1/23 | 0/19 |
| PneumoniaInfections and infestations | 1/23 | 0/19 |
| Event | HyQvia New Starters | HyQvia Pre-treated |
|---|---|---|
| CoughRespiratory, thoracic and mediastinal disorders | 8/23 | 6/19 |
| RhinitisInfections and infestations | 3/23 | 6/19 |
| Infusion site painGeneral disorders | 6/23 | 1/19 |
| GastroenteritisInfections and infestations | 5/23 | 0/19 |
| NasopharyngitisInfections and infestations | 5/23 | 1/19 |
| Infusion site pruritusGeneral disorders | 4/23 | 0/19 |
| PyrexiaGeneral disorders | 3/23 | 3/19 |
| Upper respiratory tract infectionInfections and infestations | 0/23 | 3/19 |
| FatigueGeneral disorders | 3/23 | 1/19 |
| Viral infectionInfections and infestations | 3/23 | 0/19 |
Safety analysis set included all participants in the full analysis set (enrolled set) who received at least one dose of HyQvia.
| Age, Continuous(Years) | HyQvia New Starters | HyQvia Pre-treated | Total |
|---|---|---|---|
| Mean | 10.3 ± 3.82 | 11.7 ± 4.33 | 11 ± 4.07 |
| Sex: Female, Male(Participants) | HyQvia New Starters | HyQvia Pre-treated | Total |
|---|---|---|---|
| Female | 5 | 3 | 8 |
| Male | 18 | 16 | 34 |
| Ethnicity (NIH/OMB)(Participants) | HyQvia New Starters | HyQvia Pre-treated | Total |
|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 |
| Not Hispanic or Latino | 23 | 19 | 42 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | HyQvia New Starters | HyQvia Pre-treated | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 22 | 19 | 41 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 1 | 0 | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Access criteria: IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.
Data sharing details ↗ · vivli.org
Ran from May 2017 to primary completion in Jan 2021, 43 months.
Results were first posted in Jan 2023, 1 year 11 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Immunoglobulin G · Hyaluronoglucosaminidase · Immunoglobulins, Intravenous
Primary Immunodeficiency Diseases →